In a prospective cohort of critically ill patients with active neoplasia hospitalized for pneumonia, Rabello and colleagues observed that among surviving patients, there was a higher frequency of a rapid response to CRP (decrease > 60% on the fourth day of therapy) when compared to non-survivors [19]. The gene discussed is CRP; the disease is susceptibility to pneumonia measurement.